Molecular Templates EBITDA 2010-2024 | MTEM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Molecular Templates ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Molecular Templates ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$77.1B
Chugai Pharmaceutical (CHGCY)	$71.1B
Takeda Pharmaceutical (TAK)	$42.6B
Sandoz Group AG (SDZNY)	$21B
Merck (MKKGY)	$19.6B
Astellas Pharma (ALPMY)	$17.5B
Summit Therapeutics (SMMT)	$15.9B
United Therapeutics (UTHR)	$15.7B
Neurocrine Biosciences (NBIX)	$15.4B
Shionogi (SGIOY)	$13B
Orion OYJ (ORINY)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.3B
Corcept Therapeutics (CORT)	$7B
Stevanato Group S.p.A (STVN)	$6.8B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ionis Pharmaceuticals (IONS)	$5B
Grifols, S.A (GRFS)	$4.7B
Ono Pharmaceutical (OPHLF)	$4.3B
Crinetics Pharmaceuticals (CRNX)	$3.7B
Recursion Pharmaceuticals (RXRX)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Centessa Pharmaceuticals (CNTA)	$2.2B
Soleno Therapeutics (SLNO)	$2.2B
NewAmsterdam Pharma (NAMS)	$2.1B
Hypermarcas (HYPMY)	$2B
Indivior (INDV)	$1.6B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Evotec AG (EVO)	$1.6B
Dyne Therapeutics (DYN)	$1.4B